Hepatic Encephalopathy: Early Diagnosis in Pediatric Patients With Cirrhosis by DARA*, Naghi et al.
1Iran J Child Neurol. 2014 Winter Vol 8 No 1 
Naghi DARA MD 1,
Ali-Akbar SAYYARI MD 1,




Hepatic Encephalopathy: Early Diagnosis in Pediatric Patients With Cirrhosis
How to Cite This Article: Dara N, Sayyari AA, Imanzadeh F. Hepatic Encephalopathy: Early Diagnosis in Pediatric Patients With 
Cirrhosis. Iran J Child Neurol. 2014 Winter; 8(1):1-11.
REVIEW ARTICLE
1. Pediatric Gastroenterology 
and Hepatology Department, 
Mofid Children Hospital, Faculty 
of Medicine, Shahid Beheshti 




Mofid Children Hospital, Pediatric 
Gastroenterology and Hepatology 




Hepatic encephalopathy refers to a variety of serious but often reversible 
neurologic abnormalities that arise when the liver cannot detoxify the portal 
venous blood (Table1) (1).
Brain dysfunction, an important component in the diagnosis of acute liver failure 
and chronic liver disease, cirrhosis results from an effect of hepatocyte failure 
on the function of the brain (1-3).
• Management of encephalopathic patients requires immediate identification 
of precipitating factors and initiation of empiric medical therapy. Current 
treatments include drugs to prevent ammonia generation in the colon.
• Long-acting benzodiazepines should not be used for treatment of 




As acute liver failure (ALF) and chronic liver disease (cirrhosis) continue to 
increase in prevalence, we will see more cases of hepatic encephalopathy. 
Primary care physician are often the first to suspect it, since they are familiar 
with the patient’s usual physical and mental status. This serious complication 
typically occurs in patients with severe comorbidities and needs multidisciplinary 
evaluation and care.
Hepatic encephalopathy should be considered in any patient with acute liver 
failure and cirrhosis who presents with neuropsychiatric manifestations, decrease 
level of consciousness (coma), change of personality, intellectual and behavioral 
deterioration, speech and motor dysfunction.
Every cirrhotic patient may be at risk; potential precipitating factors should 
be addressed in regular clinic visits. The encephalopathy of liver disease may 
be prominent, or can be present in subtle forms, such as decline of school 
performance, emotional outbursts, or depression.
“Subtle form” of hepatic encephalopathy may not be obvious on clinical 
examination, but can be detected by neurophysiologic and neuropsychiatric 
testing.
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Table 1. Classification of hepatic encephalopathy
Type A
Encephalopathy associated with acute liver failure
Type B
Encephalopathy with portosystemic bypass and no intrinsic 
hepatocellular disease
Type C
Encephalopathy associated with cirrhosis
Type D
Encephalopathy associated with disorders of the urea cycle
Therefore, prompt identification and treatment are 
necessary, since once overt encephalopathy develops 
the prognosis worsens rapidly. 
Thus, pediatric physician and other primary care 
physicians who care for patients with severe liver 
disease have an important role in identifying the 
condition. They will often see the patients when 
hepetic encephalopathy is in its early stages and its 
neuropsychiatric manifestations, such as reduced 
attention, declining or diminishing fine motor skills, or 
impaired communication are subtle.
The sudden onset and rapid reversibility of 
encephalopathy in liver disease suggest that it has 
a metabolic origin, so that the liver cannot detoxify 
the portal venous blood. The appearance of hepatic 
encephalopathy depends on three factors, including 
portosystemic shunting, alterations in the blood–brain 
barrier, and the interactions of toxic metabolites with 
the central nervous system (CNS). Various neurotoxins 
(especially ammonia) and inflammatory mediators 
have significant roles in its pathogenesis, inducing 
low-grade brain edema, and producing a wide range of 
neuropsychiatric manifestations (4).
Several hypotheses concerning the pathogenesis of 
hepatic encephalopathy have emerged in recent years, 
and a number of factors have been reported to directly 
or indirectly affect brain function in this condition. 
Ammonia and glutamine are the neurotoxins most 
often involved in this syndrome (5); others include 
inflammatory mediators, certain amino acids, and 
manganese (5,6).
Portosystemic Shunting
Blood from the intestine can be shunted around the 
liver via collateral vessels, or in the setting of severe 
liver disease, through the liver as the blood passes by 
damaged or necrotic hepatocytes. Potentially neurotoxic 
nitrogenous intestinal metabolites that normally are 
removed by the healthy liver, are found in blood 
circulation in patients with liver dysfunction. Therefore, 
hepatic encephalopathy is rare if liver function is good. 
Portosystemic shunting may cause encephalopathy, 
particularly if the patient consumes a high-protein 
diet (7). If both shunting and hepatocyte dysfunction 
are present, the patient is most vulnerable for the 
development of encephalopathy.
Changes in the Blood–Brain Barrier
The blood–brain barrier plays the important role of 
isolating the brain from various substances in the 
systemic circulation. The capillaries of the brain are lined 
by a specialized endothelium, which is impermeable to a 
large number of substances. These endothelial cells have 
no fenestrations otherwise seen in capillaries all over 
the body. In acute liver failure, the blood–brain barrier 
goes through changes in permeability, so that marker 
substances such as inulin, horseradish peroxidase, and 
trypan blue pass to the brain more readily (8). Therefore, 
the neurotoxins may directly mediate the changes in 
blood–brain barrier permeability (9). Although change 
in the permeability of the blood–brain barrier is seen in 
the latter stages of encephalopathy, no evidence exists 
for changes that precede the onset of encephalopathy 
(10). Zinc, which has a regulatory function in gene 
transcription and synaptic plasticity, accumulates 
in the astrocytes, causing relative zinc deficiency 
and further affecting neurotransmitter synthesis and 
neurotransmission at the neuronal synapse (6,11).
Toxic Metabolites 
Many potentially toxic substances have been isolated 
from the blood, CSF, or brain tissue of humans with 
hepatic encephalopathy. None of these has been shown 
to be responsible for the mental changes that accompany 
chronic liver disease and cirrhosis. However, hepatic 
encephalopathy can occur if toxic nitrogenous substances 
ingested or formed in the intestine, reach the brain (via 
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a “porous” blood–brain barrier) after incomplete hepatic 
removal, due to either impaired function of hepatocytes 
or collateral circulation bypass of the liver (12). The 
CNS of patients with cirrhosis is hyper-responsive to 
these circulating toxins (13). 
Ammonia causes brain swelling
Ammonia is considered an important factor in producing 
encephalopathy. Ammonia is the byproduct of bacterial 
metabolism of protein and nitrogenous compounds in the 
colon and of glutamine metabolism in enterocytes (14). 
Up to eighty percent is removed from the portal vein 
blood in its “first pass” from the gut. Hyperammonemia 
can also be seen in other encephalopathies, such as 
Reye’s syndrome and organic acidemias. Gut-absorbed 
ammonia is delivered by the portal vein to the liver, 
wherein most of it is metabolized into urea, and a small 
amount is left to be metabolized in the muscles, brain, 
heart, and kidneys (15). In cirrhosis, less ammonia 
is metabolized into urea and more of it reaches the 
astrocytes in the brain. The brain does not have a 
urea cycle, but metabolizes ammonia to glutamine 
by glutamine synthase, an enzyme that is unique to 
astrocytes. Ammonia causes swelling of astrocytes and 
brain edema by production of glutamine, an osmotically 
active substance.
Glutamine causes swelling, oxidative stress
Glutamine draws water into astrocytes and causes 
changes of type II astrocytosis (also called Alzheimer 
type II astrocytosis) (5), characterized by swelling, 
enlarged and pale nuclei, and displacement of chromatin 
to the periphery of the cell.
Glutamine also facilitate the activation of various 
receptors, including N-methyl-D-aspartate (NMDA) 
receptors (15,16), gamma-aminobutyric acid (GABA) 
receptors, and peripheral-type benzodiazepine receptors 
on the mitochondrial membrane (17–19). Other 
inflammatory mediators such as interleukins 1 and 6, 
tumor necrosis factor, interferons, and neurosteroids can 
contribute to edema and neurotoxicity (6,17). Increased 
concentrations of short- and medium-chain fatty acids 
also are seen in subjects with hepatic encephalopathy. 
High levels are seen in patients with coma; lower levels 
are associated with lesser degrees of encephalopathy (20).
Hyponatremia
Hyponatremia (serum sodium concentration<130 
mmol/L) is increasingly being recognized as an 
independent predictor of overt hepatic encephalopathy 
and is reported to raise the risk by a factor of eight (21).
Low-grade brain edema
Brain edema occurs in all forms of hepatic 
encephalopathy, but in cirrhosis it is characteristically 
of low grade. The mechanism of this low-grade edema 
has not been known yet. Studies have shown that 
astrocytes’ swelling is not global, but includes certain 
parts of the brain and is associated with compensatory 
extrusion of intracellular myoinositol (22). This, in 
concomitant with a mild degree of brain atrophy (23) 
seen in patients with chronic liver disease, is assumed 
to keep the brain from extreme swelling and herniation, 
a phenomenon which is usually seen in acute hepatic 
failure (24,25)
Transjugular intrahepatic portosystemic shunting 
and encephalopathy
The incidence rate of hepatic encephalopathy after 
placement of a porto-systemic shunt for treatment 
of portal hypertension ranges from 30% to 55% and 
is comparable to the rate in cirrhotic patients without 
a shunt (26) In 5% to 8% of patients, the hepatic 
encephalopathy is refractory and needs intentional 
occlusion of the shunt (26,27) Whether to place a 
portosystemic shunt in a cirrhotic patient, and a history 
of hepatic encephalopathy depends on the feasible 
underlying causes of the encephalopathy. For instance, 
if encephalopathy was precipitated by variceal 
bleeding, shunt placement will prevent further bleeding 
and a recurrence of encephalopathy will occur less 
likely. However, if the encephalopathy is persistent 
and uncontrollable, shunt placement is contraindicated 
(27).
• Clinical manifestations
The spectrum of symptoms ranges from a subclinical 
syndrome that may not be clinically obvious (early-stage 
or “minimal” hepatic encephalopathy) to full-blown 
neuropsychiatric manifestations, such as cognitive 
impairment, confusion, slow speech, loss of fine motor 
skills, peripheral neuropathy, asterixis, clonus, the 
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Babinski sign, decelerate and decorticate posturing, 
seizures, extrapyramidal symptoms, and coma (4). The 
clinical manifestations can be reversible with prompt 
treatment, but recurrence is common, typically induced 
by an event like infection or gastrointestinal bleeding. 
Table 2. Clinical Stages of Hepatic Encephalopathy
Clinical Manifestations Asterixis EEG changes
Stage I (prodrome)
Slowness of mentation, mild
disturbed sleep–awake cycle
Slight Minimal























or decorticate, response to
pain present (IV A)





• Minimal hepatic encephalopathy is important to 
recognize.
Although this subclinical syndrome is a very early stage, 
however it is associated with higher rates of morbidity 
and can affect life quality) 28,29) Abnormal changes in 
the brain commence at this stage and finally progress to 
more damage and to the development of overt clinical 
symptoms. The precise prevalence of minimal hepatic 
encephalopathy is unknown, because it is difficult to 
diagnose, but reported rates range from 30% and 84% 
of patients with cirrhosis (30). The most typical sign of 
CNS dysfunction is asterixis, a flapping tremor that is 
demonstrated if the patient’s arms are outstretched and 
wrists are hyperflexed. There is no tremor at rest but 
it appears during voluntary movement. Asterixis also 
is seen in uremia, respiratory failure, and congestive 
heart failure. Deep tendon reflexes may be exaggerated 
in early encephalopathy, but in the late stages, the 
muscles become flaccid and the reflexes disappear. 
Hyperventilation suggests an extremely poor prognosis.
Therefore, minimal hepatic encephalopathy is important 
to be recognized (28), so that treatment can be initiated.
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Overt encephalopathy and survival
When encephalopathy develops, the prognosis 
deteriorates rapidly. In patients who do not undergo liver 
transplantation, the survival rate at one year is 42%, and 
the survival rate at three years is 23% in adult groups 
(31). These rates are worse compared to those after liver 
transplantation, and the American Association for the 
Study of Liver Diseases recommends that patients with 
cirrhosis who develop a first episode of encephalopathy 
be considered for liver transplantation and be referred 
to a transplantation center (32).
• Challenges in diagnosis
whereas the symptoms of hepatic encephalopathy are 
not specific and can be subtle in the early stage, its 
diagnosis can be a challenge.
In subclinical hepatic encephalopathy, the obvious lack 
of manifestations causes a great diagnostic challenge, 
but a complete history may reveal personality changes, 
poor social interaction, and poor performance at work.
Primary care physicians are usually the first to suspect 
the condition, since they are familiar with the patient’s 
baseline mental and physical conditions. For instance, 
the primary care physician may recognize decreased 
attention and deterioration of memory during a follow-
up visit, or the physician may ask whether the patient 
has difficulty in work performance and handwork 
(psychomotor and fine motor skills). Changes in 
the electroencephalogram are nonspecific, but 
electroencephalography can be used for monitoring 
hepatic encephalopathy (33). At first, a generalized 
slowing of the pattern and some suppression of the 
alpha rhythm can be seen. With progression, a high-
voltage alpha rhythm emerges with paroxysmal waves 
of 5 to 7 cycles per second, beginning frontally. 
In deeper coma, there is a generalized slowing, and 
synchronous low-amplitude 2- to 3-cycle-per-second 
waves are recorded over the frontal lobes. In spite of the 
fact that these changes are similar to the progression of 
hepatic encephalopathy, it is obscure whether routine 
monitoring of the electroencephalogram provides any 
advantage over clinical assessment alone. Recorded 
evoked response potentials can provide some 
specificity for the diagnosis, but have little clinical use 
(34). 
Staging the severity of the encephalopathy
A scale for grading clinical encephalopathy is 
presented in Table 2. This scale is useful for assessing 
encephalopathy in older patients, but it is of little value 
in assessing neonates and infants, particularly in the 
early stages of encephalopathy. 












No study has yet been done on the neuropsychiatric 
function of children with acute hepatic encephalopathy, 
and also, an age-dependent grading scale is badly 
needed. When symptoms are overt, staging should be 
done to determine the severity of the disease. 
Hepatic encephalopathy may progress rapidly in Acute 
Liver Failure, with coma developing within hours of the 
earliest detectable signs. Symptoms often resolve if the 
precipitating factors are treated (Table 3). 
The most common precipitating factors are infections, 
dehydration, variceal bleeding, and drug toxicity.
Laboratory tests can identify of metabolic 
derangements
Although laboratory tests are not diagnostic for hepatic 
encephalopathy, they can identify metabolic disorders 
that could contribute to it. Blood ammonia levels are 
often measured in patients with cirrhosis suspected 
of having hepatic encephalopathy, but this is not a 
trustworthy indicator, because many conditions and 
even prolonged application of tourniquet during blood-
drawing can elevate blood ammonia levels (Table 4).
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Imaging can help exclude other diagnoses
Conventional imaging studies of the brain, i.e., computed 
tomography scan (CT scan) and magnetic resonance 
image (MRI), are useful only to exclude a stroke, a brain 
tumor, or an intracranial or subdural hematoma.
• Several lines of treatment
Treatment of hepatic encephalopathy involves a 
preemptive approach to address potential precipitating 
factors, medical therapy to decrease the production and 
absorption of ammonia from the gut, and surgical or 
interventional therapies. 
A multidisciplinary approach for testing the severity 
of neurologic impairment and response to therapy 
is required to assist determine if and when liver 
transplantation is needed.
Table 4. Conditions That May Cause Elevated 
Ammonia Levels
Bacterial overgrowth (may be seen in proton pump inhibi-
tor intake and atrophic gastritis)
Citrullinemia




Inherited disorders of urea cycle
Poor assay technique, e.g., prolonged use of a tourniquet, 




Prevention of potential precipitating factors
An important concept in managing hepatic 
encephalopathy is to recognize that every cirrhotic 
patient is at risk and to make an effort to address potential 
precipitating factors in regular clinic visits. This includes 
review of medication dosing, adverse effects and other 
toxic substances, and prevention of bleeding from 
esophageal varices by endoscopic band ligation.
Diet therapy
The prevalence of malnutrition in cirrhosis may be as 
high as 100%. All dietary and intravenous protein intake 
should cease during the acute onset and treatment. 
Protein may be reintroduced while the encephalopathy 
subsides. Vitamin and nutritional deficiencies should 
be assessed by a nutrition specialist, and nutritional 
needs should be re-evaluated on a regular basis. Protein 
restriction is no longer recommended and may even be 
hurtful. Guidelines of the European Society of Parenteral 
and Enteric Nutrition in 2006 recommended that patients 
with liver disease should have an energy intake of 35 
to 40 kcal/kg of body weight daily, with a total daily 
protein intake of 1.2 to 1.5 mg/kg of body weight (35).
Cleansing enemas may decrease further the amount of 
exogenous ammonia in the intestine, especially if hepatic 
encephalopathy follows a gastrointestinal hemorrhage.
Frequent meals and bedtime snacks are helpful to 
avoid periods of prolonged fasting and muscle protein 
catabolism and to improve nitrogen balance. Branched-
chain amino acids and vegetable protein supplements are 
recommended to help meet the daily requirements (36).
Drug therapy to reduce neurotoxins
Drug treatment is directed at decreasing the neurotoxins 
which accumulate in cirrhosis. A variety of agents have 
been used.
Lactulose (β-galactosidofructose) is a semisynthetic 
disaccharide, is a mainstay of treatment for hepatic 
encephalopathy (37,38). It has been shown to improve 
life quality and cognitive function in patients with 
cirrhosis and minimal hepatic encephalopathy, although 
it has failed to ameliorate rates of mortality (39). 
Lactulose, a cathartic disaccharide, is metabolized into 
short-chain fatty acids by colonic bacteria. The acidic 
microenvironment has three major effects:
• It helps the transformation of ammonia to ammonium 
(NH4+), which is then trapped in the stool, leaving 
less ammonia to be absorbed;
• It has a cathartic effect;  
• It decreases the breakdown of nitrogenous compounds 
into ammonia (40) 
Lactulose has an extremely sweet taste. Its adverse 
effects include flatulence, abdominal discomfort, and 
diarrhea. The adult dosage of lactulose is 10–30 mL of 
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is not necessary, and benzodiazepines should not be 
used. Morphine or other opiates may be used in small 
doses to relieve pain related to monitoring and catheter 
placement. It is difficult to maintain fluid balance because 
of the competing forces of a large intake requirement 
and compromised renal function. Dextrose infusion 
is indicated to maintain blood glucose concentration. 
Maintenance fluids consist of 10% dextrose in 0.25 
normal saline.
A total sodium intake of 1.0 mEq/kg/d is usually 
adequate. Hyponatremia should not be corrected by 
administration of additional sodium, since the total body 
sodium overload is the rule. As maintaining a state of 
hypernatremia may be helpful in the prevention of 
cerebral edema (48), preventing hyponatremia through 
maintenance of constant fluid restriction would seem 
prudent. Potassium requirements may be high, 3–6 mEq/
kg/d, as guided by the serum concentration.
Upper gastrointestinal (GI) bleeding is one of the 
risk factors that prone the patient to encephalopathy. 
Thus, anemia should be corrected, maintaining the 
hemoglobin level above 12 g/dL, to provide maximum 
oxygen delivery to tissue. Coagulopathy must be 
managed conservatively; the sometimes massive needs 
for fresh frozen plasma may cause fluid overload and 
hypernatremia.
The management of elevated intracranial pressure 
(ICP) is contingent upon the administration of osmotic 
substances, usually mannitol. Mannitol is usually 
administered when alterations in the neurologic 
examination or the onset of papilledema is detected.
If intracranial pressure increases more than 30 mmHg, 
it should also be treated. The doses of mannitol required 
are usually in the range of 1 g/kg, every 2–6 hours. 
Serum osmolarity should be monitored during mannitol 
therapy and should not go beyond 320 mOsm/kg.
Branched-chain amino acids (leucine, isoleucine, and 
valine) (49) have been reported to elevate ammonia 
intake in muscle and to improve cognitive functions in 
minimal hepatic encephalopathy (50,51), but they did not 
reduce the rate of recurrence of hepatic encephalopathy 
(52). While debate continues over their effectiveness in 
the management of hepatic encephalopathy, branched-
chain amino acids may be used to improve nutritional 
status and muscle mass of cirrhotic patients. However, 
the standard syrup (10 g lactulose/15 mL), three times 
a day. Pediatric dosage is 0.3–0.4 mL/kg, two or three 
times per day. The dose should be sufficient to acidify 
the stools (pH less than 6.0) but should not necessarily 
cause diarrhea.
Lactitol, is a nonabsorbable disaccharide that its mode of 
action is the same as that of lactulose. Its main advantage 
is that it is produced in a powder form and is thus less 
sweet and more convenient for use than lactulose. 
Furthermore, it is not contaminated (as lactulose syrup) 
with lactose, galactose, and other sugars; therefore, it is 
more acceptable in patients who are lactose intolerant. It 
seems to be as efficient as lactulose in the treatment of 
acute and chronic hepatic encephalopathy and has been 
found to have a more rapid effect compared to lactose, 
but with fewer side effects (41).
Neomycin: Oral antibiotics have been used successfully 
in children for the treatment of early hepatic 
encephalopathy. Tetracycline is used in adults, but is 
not appropriate for use in children. Neomycin decreases 
ammonia production, presumably through direct 
suppression of ammonia forming bacteria (42,43).
Long term use of neomycin has caused deafness and 
renal tubular disease (44,45). The adult dosage of 
neomycin is 4–6 g/d. In children, a starting dose of 1 g 
is recommended.
Other antibiotics, such as metronidazole (Flagyl), 
neomycin, and vancomycin have been used as 
alternatives to lactulose, according to the principle 
that they decrease ammonia producing bacteria in the 
gut. However, their efficacy in hepatic encephalopathy 
remains to be determined. In controlled trials, neomycin 
in combination with sorbitol, magnesium sulfate, or 
lactulose had the same effectiveness as lactulose, but 
when used alone, neomycin was no better than placebo 
(46,47).
Specific therapy Management should be in an ICU 
setting. It is assumed that improved life support, 
monitoring for the detection of complications, and the 
management of life-threatening complications in an 
intensive care setting can increase the overall chance for 
survival.
The older patient with aggressive delirium is a particular 
risk to care providers. Restraint and sedation may be 
required to protect staff. However, sedation usually 
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transplantation; the nature of the neurologic deficits; 
advanced age; history of alcohol abuse and the existence 
of alcoholic brain damage; persistence of portosystemic 
shunts after transplant; emergency transplantation; 
complications during surgery; and adverse effects of 
immunosuppressive drugs (59,60,65).
The optimal timing of liver transplantation is not 
obviously defined for patients who have had bouts of 
hepatic encephalopathy, and further study is needed to 
determine the reversibility of clinical symptoms and 
brain damage. In these situations, neuropsychiatric 
testing and advanced neuroimaging can help determine 
the effectiveness of therapeutic interventions, and it 
should be considered as a part of the pretransplantation 
assessment.
Causes of Death
Cerebral edema with brain death is the direct cause of 
mortality in most children with ALF. Overwhelming 
bacterial or fungal infection is seen in a small proportion 
of patients, and pulmonary failure in very few. 
Hemorrhagic diathesis is a common reason of death in 
adult patients, but is rare in children afforded effective 
management. Therapeutic intervention may cause 
death in some patients. Experience with corticosteroid 
therapy reveals a risk of duodenal ulcer with perforation 
or hemorrhage. Extracorporal support devices are 
associated with technical failure (catheter dislodgment) 
and with numerous other complications that can lead to 
death.
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